December 8, 2025Blood

Clinical characteristics, disease progression, and vascular events in essential thrombocythemia: A single-center cohort study with long-term follow-up.

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Cohort study shows high AML and SMF progression rates in essential thrombocythemia, suggesting vascular complications relate to genetic mutations.

This research examines the clinical characteristics, disease progression, and vascular events in patients with essential thrombocythemia (ET).
Retrospective review of 90 ET patients diagnosed before 2015
Collected data on clinical, laboratory, and genetic factors
Guided by WHO 2022 criteria for ET diagnosis
11 patients progressed to acute myeloid leukemia (AML) after median 14.8 years
40 patients progressed to secondary myelofibrosis (SMF) after median 13.5 years
Genetic mutations were associated with disease progression; vascular complications occurred in 37% of patients.

Lourdes M. Mendez (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

Cohort study shows high AML and SMF progression rates in essential thrombocythemia, suggesting vascular complications relate to genetic mutations.

This research examines the clinical characteristics, disease progression, and vascular events in patients with essential thrombocythemia (ET).
Retrospective review of 90 ET patients diagnosed before 2015
Collected data on clinical, laboratory, and genetic factors
Guided by WHO 2022 criteria for ET diagnosis
11 patients progressed to acute myeloid leukemia (AML) after median 14.8 years
40 patients progressed to secondary myelofibrosis (SMF) after median 13.5 years
Genetic mutations were associated with disease progression; vascular complications occurred in 37% of patients.

Lourdes M. Mendez (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark